1392 studies found for:    "Pancreatic Neoplasms"
Show Display Options
Rank Status Study
1 Recruiting Gemcitabine and CT-011 for Resected Pancreatic Cancer
Conditions: Pancreatic Neoplasms;   Cancer of the Pancreas;   Neoplasms Pancreatic;   Pancreatic Cancer;   Pancreas Cancer
Interventions: Biological: CT-011;   Drug: Gemcitabine
2 Recruiting Combination Chemotherapy With or Without Oregovomab Followed By Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer;   Stage III Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: leucovorin calcium;   Biological: oregovomab;   Drug: nelfinavir mesylate;   Radiation: stereotactic body radiation therapy;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis;   Drug: fluorouracil
3 Recruiting DCE MRI in Diagnosing Patients With Pancreatic Cancer
Conditions: Hereditary Pancreatic Cancer;   Intraductal Papillary Mucinous Neoplasm of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Intervention: Procedure: dynamic contrast-enhanced magnetic resonance imaging
4 Completed Eribulin Mesylate as Second-Line Therapy in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Pancreatic Cancer;   Recurrent Pancreatic Cancer;   Stage II Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Intervention: Drug: eribulin mesylate
5 Recruiting Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer
Conditions: Cancer of Pancreas;   Cancer of the Pancreas;   Neoplasms, Pancreatic;   Pancreas Cancer;   Pancreas Neoplasms
Interventions: Drug: Modified FOLFIRINOX;   Radiation: Stereotactic Body Radiotherapy (SBRT)
6 Terminated RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
7 Completed CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage II Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: temsirolimus;   Other: laboratory biomarker analysis
8 Completed Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage II Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: sorafenib tosylate;   Drug: gemcitabine hydrochloride
9 Completed UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage II Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: 7-hydroxystaurosporine;   Drug: gemcitabine hydrochloride;   Other: pharmacological study;   Other: laboratory biomarker analysis
10 Completed Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage II Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride;   Biological: bevacizumab;   Other: placebo;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: pharmacological study
11 Recruiting Metformin Hydrochloride in Treating Patients With Pancreatic Cancer That Can be Removed by Surgery
Conditions: Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer
Interventions: Drug: metformin hydrochloride;   Other: pharmacological study
12 Completed
Has Results
Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage II Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Biological: cetuximab;   Drug: gemcitabine hydrochloride;   Biological: bevacizumab;   Drug: erlotinib hydrochloride
13 Recruiting Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancrease Cancer
Conditions: Pancreas Cancer;   Localized Pancreas Cancer;   Non-metastatic Pancreas Cancer
Intervention: Drug: FOLFIRINOX Regimen
14 Terminated
Has Results
Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Conditions: Intraductal Papillary Mucinous Neoplasm of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer;   Stage III Pancreatic Cancer
Interventions: Drug: erlotinib hydrochloride;   Procedure: conventional surgery;   Other: immunohistochemistry staining method;   Genetic: protein expression analysis;   Procedure: biopsy;   Other: pharmacological study;   Other: laboratory biomarker analysis
15 Active, not recruiting Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer;   Stage III Pancreatic Cancer
Interventions: Drug: dasatinib;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis;   Genetic: mutation analysis;   Genetic: nucleic acid sequencing;   Other: immunohistochemistry staining method
16 Unknown  Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer
Conditions: Adenocarincoma of Pancreas;   Stage III Pancreatic Cancer;   Stage IVA Pancreatic Cancer;   Stage IVB Pancreatic Cancer
Interventions: Drug: paclitaxel;   Drug: oxaliplatin;   Drug: leucovorin;   Drug: 5-fluorouracil;   Drug: glutathione;   Drug: calcium and magnesium;   Procedure: Chemotherapy;   Procedure: Chemoprotection;   Procedure: Complementary and alternative therapy
17 Recruiting Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed By Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: dinaciclib;   Drug: Akt inhibitor MK2206;   Other: pharmacological study;   Other: laboratory biomarker analysis
18 Recruiting PANFIRE - Pilot-study: Irreversible Electroporation (IRE) to Treat Locally Advanced Pancreatic Carcinoma
Conditions: Locally Advanced Pancreatic Carcinoma (LAPC);   Non-metastasized Unresectable Pancreatic Carcinoma;   Pancreatic Cancer
Intervention: Device: NanoKnife "Irreversible electroporation (IRE)"
19 Completed Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer
Conditions: Recurrent Colon Cancer;   Extensive Stage Small Cell Lung Cancer;   Stage III Pancreatic Cancer;   Stage III Rectal Cancer;   Limited Stage Small Cell Lung Cancer;   Recurrent Pancreatic Cancer;   Recurrent Rectal Cancer;   Stage III Non-Small Cell Lung Cancer;   Stage I Pancreatic Cancer;   Stage II Non-Small Cell Lung Cancer;   Stage IVB Pancreatic Cancer;   Stage II Pancreatic Cancer;   Stage III Colon Cancer;   Stage IVA Pancreatic Cancer
Interventions: Drug: Detox-B adjuvant;   Drug: ras peptide cancer vaccine
20 Recruiting Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Intraductal Papillary Mucinous Neoplasm of the Pancreas;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: erlotinib hydrochloride;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Drug: capecitabine;   Drug: fluorouracil;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years